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Background: The vaccine was efficiently effective against bladder cancer in earlier studies. However, a part of the
mouse bladder tumour regrew due to regression after a period of time as the cancer stem cells could not be
eliminated. In this study, we showed a modified method for the isolation of MB49 bladder cancer stem cells
(MCSCs).
Methods: Through a comparison of different serum-free culture mediums (SFM), MCSCs were isolated by a combination
of the limited dilution method and the optimal SFM method. The characterizations of MCSCs were verified by the
fluorescence activated cell sorting, the quantitative polymerase chain reaction, the western blotting, the cell
proliferation assay, the soft agar assay, the transwell assay, the resistance to chemotherapy assay and the
tumor xenograft formation assay.
Results: The optimal SFM contained a RPMI1640+ epidermal growth factor (20 ng/ml), a basic fibroblast
growth factor (20 ng/ml), a leukemia inhibitory factor (20 ng/ml), a B-27 serum-free supplement (20 μl/ml),
and a bovine serum albumin (4 μg/ml). MCSCs possessed the high expression of cancer stem cell markers
(CD133, CD44, OCT4, NANOG, and ABCG2) and the ability of differentiation. In functional comparisons, MCSCs
had higher proliferative abilities, lower susceptibility to chemotherapy, greater migration in vitro, and stronger
tumorigenic abilities in vivo.
Conclusion: MCSCs displayed specific cancer stem cells properties. Our study showed MCSCs were isolated
successfully with a modified method using a combination of limited dilution and SFM methods.
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The MB49 bladder cancer cell vaccine induced a specific
antitumor immunity and was efficiently effective against
metastatic bladder cancer in our earlier studies [1-3].
However, we also found that a part of the mouse
bladder tumor regrew after experiencing regression
for a period of time because the cancer stem cells
(CSCs), or cancer-initiating cells, could not be eliminated.
Recent findings supported the notion that relapses of solid
tumors may be attributed to the inability of traditional
chemotherapies and radiotherapies to eradicate CSCs [4].
Our former bladder cancer vaccine was not the CSC* Correspondence: tanwanlong@gmail.com
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stated.vaccine, which was unable to induce specific immunities
responsible for CSCs.
Limited dilution assays were first used to establish
CD133+ single cell-derived progenies of colorectal
cancer in 2010 [5]. The serum-free culture medium
(SFM) method had been used to isolate CSCs from
tumors, but it was limited due to the lack of purity
in the CSCs [6]. As we known, the combination of
the limited dilution method and SFM method has not
been used to isolate the CSCs, which could improve
the purity of cell sorting. Cancer stem cells from a
MB49 bladder cancer cell line (MCSCs) had not been
demonstrated before, and the isolation of MCSCs would
provide a model for the development of bladder cancer
vaccine research. We provide a modified method here by. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Table 2 Combination of medium and supplements
No. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
EGF √ √ √ √ √ √ √ √ √
FGF-b √ √ √ √ √ √ √ √ √
LIF √ √ √ √ √ √ √ √ √
B27 √ √ √ √ √ √ √ √ √
BSA √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √
RPMI 1640 √ √ √ √ √ √ √ √ √ √ √ √ √ √ √
DMEM/F12 √
Table 3 Primers of selected genes
Gene name Primers (forward/reverse) Base pairs
of product
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isolate MCSCs.
Methods
Optimal SFM for MCSCs
The mediums reported previously to support the expansion
of CSCs were different [7,8]. Furthermore, the defined SFM
formulations reported in previous literature have not been
able to support the MCSCs. Based on these considerations,
a sequential approach was taken to identify defined SFMs
for the successful isolation and expansion of MCSCs.
The culture media and recombinant growth factors
tested are shown in Table 1. The epidermal growth factor
(EGF), fibroblast growth factor basic (FGF-b), leukemia
inhibitory factor (LIF), and the B-27 serum-free sup-
plement (B27) have previously supported the expansion
of different kinds of CSCs [9,10]. The most important
serum substitute is bovine serum albumin (BSA), and
the optimized concentration of BSA is 0.4% [11]. The
different combinations shown in Table 2, e.g. No. 5 are
EGF + B27 + BSA + RPMI1640.
Cell culture for the MB49 cell line
The murine bladder cancer cell line, MB49, was a gift
from Dr. I. C. Summerhayes from the Lahey Clinic in
Burlington, Massachusetts [1-3]. MB49 cells were cultured
in RPMI1640 that contained 10% fetal bovine serum
(FBS, Thermo Scientific HyClone, Logan, Utah) at 37°C in
a 5% CO2 humidified incubator.
Comparison of culture medium and supplements
The accutase-enzyme cell detachment medium (Accutase,
eBioscience, San Diego, California) was used for digestion.
Then the different culture mediums were added to dilute
the Accutase in order to stop digestion. Finally, the MB49
cells were dissociated into the single cell suspension and
seeded at a density of 2 × 103 cells per well as shown in
Table 2. There were various culture mediums in 96-well
plates with ultra low attachment surface (Corning Life
Sciences, Union City, California). Cells were incubated
for a subsequent 5 days. Then 10 μl of the Cell Counting
Kit-8 reagent (CCK-8, Dojindo Molecular Technologies,Table 1 Cell culture medium and supplements
Reagent Suppliers Concentration
EGF Peprotech, Rocky Hill, NJ, USA 20 ng/ml
FGF-b Peprotech 20 ng/ml
LIF eBioscience, San Diego, CA, USA 20 ng/ml
B27 Invitrogen, Grand Island, NY, USA 20 μl/ml
BSA Thermo Scientific HyClone, Logan, UT, USA 4 mg/ml
RPMI1640 Thermo Scientific HyClone 1×
DMEM/F12 Thermo Scientific HyClone 1×Kumamoto, Japan) were added at a fixed time in 1, 2, 3, 4,
and 5 days. After a 4 hour incubation, the absorbance
value was measured at 450 nm using an EnSpire 2300
multilabel reader (PerkinElmer, Singapore).
After 7 days, the colonies with a diameter greater than
50 μm were counted with an inverted microscope (Nikon,
Japan), and the cell morphologies in various culture
mediums were recorded with a camera (Nikon, Japan).
Establishment of MCSCs
Limited dilution method
The MB49 cells were digested with Accutase. They were
then counted and diluted tenfold at a limited 3–4 times
to form a density of 5 cells per milliliter in an optimal
SFM with plated 200 μL in a 96-well plate. Finally, single
cells were marked and observed every day.
Passage culture
The Passage 1 single cells were cultured in the optimal
SFM, and we removed the supernatant and supplemented
fresh SFM every 5–7 days. By the 30th day, the single cells
had grown to single-cell spheres so large that they were
visible. They were digested with Accutase, dispersed
mechanically, and plated in a 24-well plate with an ultra
low attachment surface (Corning Life Sciences) before
forming passage 2 cells.CD133 F: 5’-CGGGATCCGAAAAACTGATCTGT-3’ 615 bp
R: 5’-CCGCTCGAGTTACCTAGTTACTCTCTCC-3’
CD44 F: 5’-CCCTGCTACCAGAGACCAAGAC-3’ 401 bp
R; 5’-GCAGGTTCCTTGTCTCATCAGC-3’
NANOG F: 5’-CAGCTGTGTGTACTCAATGATAGATTT-3’ 179 bp
R: 5’-ACACCATTGCTATTCTTCGGCCAGTTG-3’
OCT4 F: 5’-TCAGCCAAACGACCATCTGC-3’ 205 bp
R: 5’TTCTCCAGGTTGCCTCTCAC-3’
GAPDH F: 5’-CCATGGAGAAGGCTGGGG-3’ 198 bp
R: 5’-CAAAGTTGTCATCCATGACC-3’
Table 4 Concentrations of chemotherapeutic agents
Agents Concentrations
Paclitaxel 10 nM 100 nM 1 μM 10 μM
Doxorubicin 10 nM 100 nM 1 μM 10 μM
Cisplatin 5 μM 10 μM 15 μM 20 μM
Mitomycin 10 μM 80 μM 640 μM 5.12 mM
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SFM every 3–4 days. By the 15th day, most of the cells
had grown to spheres large enough to view. Then the
spheres were collected, centrifuged for 5 minutes at
800 rpm, digested with Accutase, dispersed mechanically,
and plated in a 6-well plate with an ultra low attachment
surface (Corning Life Sciences) before forming passage 3
cells. The cells had expanded to a T25 culture flask
(Corning Life Sciences) through multiple passages using
the same protocol.Characterizations of MCSCs
Expression of MCSCs markers
Fluorescence activated cell sorting (FACS) The MB49
cells and MCSCs were harvested respectively. They
were dissociated at a density of 1 × 104 cells in a
100 μl autoMACS running buffer (Miltenyi Biotec,
Bergisch Gladbach, Germany), labeled with 20 μl PE
mouse anti-prominin-1 (Miltenyi Biotec) and FITC mouse
antiCD44 (Miltenyi Biotec), incubated for 20 minutes at
4°C, and washed twice with phosphate buffered saline
(PBS). To set the background fluorescence levels, we used
the PE rat IgG1 κ isotype control (eBioscience) and the
TITC rat IgG2b κ isotype control (eBioscience) as the nega-
tive control. The ratio of CD44+CD133+ cells was evaluated
using a BD FACSAria cell sorter (Becton-Dickinson, San
Jose, California).Quantitative polymerase chain reaction (qPCR)
The total RNAs extracted were isolated by using the
Arcturus PicoPure RNA isolation kit (Applied Biosciences,
Carlsbad, New Mexico). The RNA quality was verified by
the Bioanalyzer RNA Pico Chip (Agilent Technologies,
Santa Clara, California). The two micrograms of total
RNA were reverse transcribed with Superscript III
(Invitrogen, Grand Island, New York) to synthesize
the first-strand cDNA. The cDNA was amplified with
SYBR green PCR master mix (Bio-Rad, Hercules, California)
on a 7500 real time PCR system (AB Applied Biosystems,
Singapore). The cycling conditions were 95°C for 10 s
(denaturation) and 60°C for 60 s (annealing and extension).
The primer sequences are listed in Table 3. Normalization
and fold changes were calculated using the ΔΔCt method
[12]. The gene expression of GAPDH was used as a
negative control.Western blotting (WB) Equal amounts of the protein
samples extracted were separated with 10% sodiumdode-
cyl sulfate -polyacrylamide gel and transferred to poly-
vinylidene difluoride membranes (Millipore, Billerica,
Massachusetts) electrophoretically. Filters were blocked
in the PBS with 5% skim milk and incubated overnight
at 4°C with the primary antibody anti-OCT4 (Abcam,
Cambridge, Massachusetts), anti-NANOG (Abcam), anti-
ABCG2 (Abcam), and anti-β-actin antibody (Abcam). The
filters were then incubated with conjugated anti-mouse
secondary antibodies (Abcam)[13]. The protein bands
were detected by Fluor Chem FC2 (Alpha Innotech,
San Leandro, California) and analyzed by Image Lab
software.
Differentiation
The MCSCs were collected, dissociated into single cells,
and cultured in RPMI1640 supplemented with 10% FBS
to induce cell differentiation. Meanwhile, the MCSC
spheres were cultured by the same method.
Functional comparison
Cell proliferation assay The cells were plated at a number
of 1 × 103 in a 96-well plate and incubated for 1, 2, 3,
4, 5, and 6 days respectively. We then added 10 μl
CCK-8, the samples were incubated for 4 hours, and
the absorbance values were measured as before.
Soft agar assay The cells were resuspended at a density
of 1 × 104/ml with a bottom of 0.66% agar (Beyotime,
Jiangsu, China) while the medium was supplemented
with 10% FBS and layered on the top was a 1.32% agar
supplemented with 20% FBS on 6-well plates respectively
[13]. The plates were incubated for three weeks, and
then the colonies with diameters greater than 50 μm
were counted.
Migration abilities in vitro The cells were seeded at a
number of 1 × 104 in 0.25 ml of pure RPMI1640 on a
6.5-mm pore-size polycarbonate membrane chamber
inserted in a transwell apparatus (Costar, Cambridge,
Massachusetts). 0.75 ml of the RPMI1640 medium that
contained 10% FBS was added to the lower chamber.
Then the cells were incubated for 24 hours. The cells
that had migrated to the bottom surface of the insert
were fixed in paraformaldehyde for 20 minutes, stained
in giemsa for 15 minutes, rinsed in PBS, and inspected
via inverted microscopy.
Resistance to chemotherapy abilities The cells were
seeded at a number of 1 × 104 in a 96-well plate. After
24 hours, the chemotherapeutic agents mitomycin
(Sigma-Aldrich, St. Louis, Missouri), cisplatin (Sigma-Aldrich),
paclitaxel (Sigma-Aldrich), and doxorubicin (Sigma-Aldrich)
Figure 1 Comparison of culture mediums and supplements for MB49 cell cultures. The combination for an optimal SFM is RPMI1640+ EGF
(E) + FGF-b(F) + LIF(L) + B27(B) + BSA. (A) SFM with the combination of all four growth factors E + F + L + B together provides a robust synergistic effect
on MB49 cell morphology. The medium containing just one or two growth factors displays small sphere morphology. (B) The cell proliferation curve
shows that the combination of E + F + L + B contains the highest absorbance value after using the Cell Counting Kit-8(CCK-8). (C) The largest numbers
of colony-forming units is the combination of E + F + L + B. (D) The highest sphere-formation efficiency is the combination of E + F + L + B.
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The cells were treated for a subsequent 96 hours.
Therefore, 10 μl of CCK-8 were added to each well,
and after 4 hours of incubation, the absorbance values
were measured. The cell viability that corresponded
to each drug treatment was expressed as the percentage of
absorbance values of the treated wells related to the
untreated control wells [12].
Tumorigenic abilities in vivo All of the experimental
procedures with animals used in the present study have
been given prior approval by the Ethics Committee of
Southern Medical University under Contract 2011016.4-week-old immune deficient nude mice (Center of
Experimental Animals, Southern Medical University,
Guangzhou, China) were maintained and treated under
specific, pathogen-free conditions. The cells were injected
with gradient concentration subcutaneously into the nude
mice, at a number from 1 × 102 to 1 × 104 in MCSCs
and from 1 × 104 to 1 × 106 in MB49 cells. The tumor
xenograft formation was observed every week. At the
end of eight weeks, the mice were sacrificed by cervical
dislocation, the tumor engrafts were removed, and the
volume of tumors was measured by using the formula
d2 × D/2, where d and D were the shortest and the longest
diameters respectively [14].
Figure 2 Morphology of MCSCs under serum-free medium and medium containing 10% fetal bovine serum (FBS). (A) Representative
example of a CSC sphere formation originating from a single MB49 cell under an optimal serum-free culture medium. (B) MCSCs generated secondary
passages. (C) MCSCs are differentiated and adherent to the culture dish when cultured in medium containing 10% FBS. (d = day; P = passage).
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SPSS19.0 software was used for the statistical evaluations.
All of the data was expressed as the mean ± standard
deviation and analyzed using one-way ANOVA. P < 0.05
was considered statistically significant.
Results
Comparison of culture medium and supplements for
MB49 cell culture
The SFM with the combination of all four growth factors
(EGF, FGF-b, LIF, and B27) together provided a robust
synergistic effect on cell proliferation. The medium
contained just one or two growth factors and displayed
small sphere morphology (Figure 1a). The cell prolifera-
tion curve showed that the combination of EGF, FGF-b,
LIF, and B27 contained the highest absorbance value using
CCK-8 (Figure 1b). The numbers of colony-forming units
and colony-forming efficiencies showed the same trend
(Figure 1cd). The cells grown in DMEM/F12 displayed a
similar colony-forming potential compared to those grownin RPMI1640. The combination of the optimal SFM was
RPMI1640 + EGF (20 ng/ml) + FGF-b(20 ng/ml) + LIF
(20 ng/ml) + B27(20 μl/ml) + BSA(4 μg/ml).
Establishment of MCSCs in SFM
The limited dilution method showed that only a 2–3
percentage of MB49 cells generated CSC spheres in
SFM. The passage 1 single MB49 cell formed a CSC
sphere within 30 days in optimal SFM. The MCSCs were
passaged after 15 days to form new tumor spheres, and
most MCSCs generated secondary spheres. (Figure 2ab).
Characterizations of MCSCs
Expression of CSCs markers
As demonstrated by the FACS analysis, the fraction of
CD44+ cells in MB49 cells was higher than that of
MCSCs. However, the fraction of CD133+CD44+ cells
was 19.83 ± 0.68% in MCSCs and 3.57 ± 0.38% in MB49
cells, which was elevated in MCSCs relative to MB49
cells (P < 0.05, Figure 3a).
Figure 3 Comparison of specific markers in MCSCs and MB49 cells. (A) (up) In the fluorescence activated cell sorting analysis, the fraction of
CD44+ cells in MB49 cells is higher. However, the fraction of CD44+CD133+ cells is higher in MCSCs than in MB49 cells. (down) The fraction of CD44
+CD133+ cells is 19.83 ± 0.68% in MCSCs and 3.57 ± 0.38% in MB49 cells, which is elevated in MCSCs relative to MB49 cells. (B) The comparison of
quantitative polymerase chain reaction analysis shows that the expression of CD133, CD44, OCT4 and NANOG are higher in MCSCs than in MB49 cells.
(C) (left) The pattern of OCT4, NANOG and ABCG2 expression using western blot. β-actin is used as a positive control. (right) Comparison of western
blot analysis shows that OCT4, NANOG and ABCG2 are sparsely distributed in MB49 cells but are abundantly expressed in MCSCs. (*P < 0.05).
Zhu et al. BMC Urology 2013, 13:57 Page 6 of 9
http://www.biomedcentral.com/1471-2490/13/57The relative levels of CD133, OCT4 and NANOG
were higher in MCSCs using the qPCR experiment,
being 5 times as high as observed in MB49 cells.
However, the level of CD44 was higher in MB49 cells
(P < 0.05, Figure 3b).
OCT4, NANOG and ABCG2 were both expressed in
MCSCs and in MB49 cells by the WB assay. They
were sparsely distributed in MB49 cells, but they were
abundantly expressed in MCSCs (P < 0.05,Figure 3c).Differentiation
MCSCs were globular and floating in SFM. When the
MCSCs were reseeded with a medium containing 10%
FBS, they became flat after being differentiated and
attached to the culture dish (Figure 2c).Functional comparison
MCSCs increased the proliferation as compared with
MB49 cells in the SFM on day 4, 5, 6 after using CCK-8
in the cell proliferation assay (P < 0.05; Figure 4a). The
soft agar assay revealed that MCSCs formed bigger and
more numerous colonies than MB49 cells did (P < 0.05;
Figure 4b). Both assays showed that MCSCs possessed
highly proliferative abilities.Under the same incubation conditions, the number
of invaded MCSCs were more than that of MB49
cells (P < 0.05; Figure 4c). Transwell migration assays
displayed that MCSCs contained higher transmembrane
activity than MB49 cells.
Compared to MB49 cells, MCSCs showed higher cell
viabilities after being treated with different concentrations
of mitomycin, cisplatin, paclitaxel, and doxorubicin in
Figure 4d. MCSCs demonstrated lower susceptibility to all
these traditional anticancer agents.
MCSCs caused a more remarkable tumor volume than
MB49 cells did. Immune deficient nude mice injected with
1 × 106 in MB49 cells or 1 × 103 in MCSCs formed xeno-
grafts, those injected with 1 × 105 in MB49 cells or 1 × 102
in MCSCs did not. The morphology of H&E stained xeno-
graft tumor sections from MCSCs resembled tumor tissue
from MB49 cells (Figure 4e). Xenograft formation showed
that MCSCs possessed strongly tumorigenic ability in vivo.
Discussion and conclusions
To facilitate the transition of MCSCs to vaccine applications,
advances in expanding MCSCs had become an absolute
necessity. There were three methods that have been
used to isolate CSCs from tumors: specific cell surface
markers, SFM, and side population cells. These methods
Figure 4 Functional characteristics comparison in MCSCs and MB49 cells. (A) Comparison of proliferative abilities. The cell proliferation
growth curve using CCK-8 shows that MCSCs contain the higher absorbance value at day 4,5,6. (B) (left) The light images of soft agar assay shows that
MCSCs form more numerous and bigger colonies than MB49 cells. (right) The comparison of colony number shows that MCSCs cause a significant
increase in colony numbers on soft agar than MB49 cells do. (C) Comparison of migration abilities in vitro. (left) The light images of penetrating cells
by transwell migration assays. (right) The numbers of invaded MCSCs are more than MB49 cells. (D) Comparison of resistance to chemotherapy using
CCK-8. Compared to MB49 cells, MCSCs show higher cell viabilities after treatment with various concentrations of anti-cancer drugs including paclitaxel,
doxorubicin, cisplatin and mitomycin. The viability is presented as% of viable cells after drug treatment relative to number of untreated control cells.
Data is the mean ± SD of three independent experiments. (E) Comparison of tumorigenic abilities in vivo. (left) The light images of subcutaneously
tumorigenicity by xenograft formation in deficient nude mice. (middle) MCSCs cause remarkable tumor volume than MB49 cells do following an
injection of the same number. (right) Microphotographs of H&E stained tumor tissue sections from MCSCs and MB49 cells. (*P < 0.05).
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purity was not enough for CSCs [6]. Limited dilution
assay was mostly used to assess the tumorigenic activity of
xenograft cells [15]. However, the limited dilution method
in our study was different, which allowed MCSCs sphere
formation to originate from a single cell before improving
the purity of CSCs (Figure 5). The limited dilution method
showed that only a small percentage of MB49 cells
generated CSC spheres, and the proportion was similar to
other scholars’ results [16].
Considering that the serum caused irreversible differen-
tiation of stem cells, SFM selection might be useful for
CSCs expansion and would allow for maintenance of an
undifferentiated stem cell status [17]. Accutase, which
is one kind of digested enzyme, was different from
trypsin and did not need serum to stop digestion.Accutase stopped digestion by adding 50 times as
much SFM to dilute the enzyme, so MCSCs could
maintain an undifferentiated status.
Due to the heterogeneity of different cancers, the optimal
medium for the growth of CSCs may vary from case to
case. A supplement medium that is critical to one line may
be of no benefit or even adverse to the other. Therefore, it
is recommended to perform experiments by choosing the
optimal supplement composition for the MB49 cell line.
Our study suggests that the medium should contain four
stimulated factors: LIF, B27, EGF and FGF-b, which would
together provide an optimal sphere formation with the
MCSCs having survived continuous passage in culture. In
contrast, MB49 cells do not proliferate and expire under
SFM during serial passages. To our knowledge, this is the
first report about the isolation and expansion of MCSCs via
Figure 5 Diagram illustration to the proposed model for isolation of MCSCs by combination of limited dilution method and optimal
SFM method.
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is modified to improve the purity of CSCs.
CD133 and CD44 have been used to identify CSCs from
other cancer tissues [18,19]. Interestingly, our results showed
an elevated CD44+CD133+ expression in MCSCs. OCT4
played a significant role in self-renewal [20], and NANOG
was identified as a key molecule to maintain self-renewal
and to block differentiation [21]. These genes can poten-
tially lead to tumorigenesis and affect some cancer behav-
iors, such as resistance to therapies or cancer recurrence[6].
They were not only upregulated at the protein level (WB)
but also at the mRNA transcript level (qPCR) in MCSCs.
The capability to differentiate was another important
feature of CSCs [8]. Furthermore, we applied the tech-
niques to functionally characterize MCSCs populations
[22,23]. MCSCs had typical CSCs that were capable of
self-regeneration with a higher proliferative capacity and
greater colony formation potential. MCSCs showed the
greater capacity to penetrate wells, which indicated that
these cells were the most likely to migrate.
Chemotherapy killed the majority of cells in a tumor, but it
did not kill CSCs, which might be the mechanism behindthe resistance to chemotherapy [24,25]. MCSCs had a lower
susceptibility to mitomycin, cisplatin, paclitaxel and doxo-
rubicin. The ATP-binding cassette (ABC) transporters ex-
plained the mechanism that many chemical drugs were
pumped out of cells by ABC transporters [26]. MCSCs
showed a higher level of ABCG2 expression at the protein
level (WB), and the upregulation of ABCG2 was asso-
ciated with the resistance of MCSCs to anti-cancer
drugs. The standard experimental method for the isolation
of CSCs was to test the tumorigenicity of cancer cells in
immunodeficient mice [27]. MCSCs showed the greatest
ability to form tumors in the subcutaneous tissues of
immunodeficient mice.
Taken together, this data showed that cultured MCSCs
displayed specific CSC properties. In conclusion, MCSCs
were isolated successfully with a modified method
using a combination of limited dilution and SFM methods.
MCSCs contained characteristics resembling CSCs
such as in vitro self-renewal, a differentiation potential,
chemotherapy resistance and in vivo tumorigenic capacity.
MCSCs may provide an ideal model for the development
of bladder cancer vaccine research.
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